AbbVie Inc. $ABBV Shares Sold by Dearborn Partners LLC

Dearborn Partners LLC reduced its position in AbbVie Inc. (NYSE:ABBV) by 18.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 141,951 shares of the company’s stock after selling 32,095 shares during the period. AbbVie comprises about 1.6% of Dearborn Partners LLC’s portfolio, making the stock its 16th biggest holding. Dearborn Partners LLC’s holdings in AbbVie were worth $32,434,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in ABBV. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie in the 3rd quarter valued at $31,000. Legacy Wealth Managment LLC ID lifted its stake in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the period. Finally, WestEnd Advisors LLC lifted its stake in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on ABBV. Piper Sandler boosted their target price on shares of AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Barclays began coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.43.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s ovarian cancer drug Elahere received a green light from the UK’s NHS / drug-cost watchdog, improving access and potential sales in a major international market. British drug-cost watchdog recommends use of AbbVie’s ovarian cancer therapy
• Positive Sentiment: AbbVie also won European Commission approval for Aquipta to treat migraine, which could expand the drug’s commercial opportunity in Europe. AbbVie receives EC approval for Aquipta to treat migraine
• Positive Sentiment: AbbVie’s FDA approval of Decnupaz for BPDCN was highlighted as validation of its ADC oncology strategy, reinforcing confidence in the company’s long-term cancer pipeline. Does Decnupaz Approval Validate ABBV’s ADC Strategy in Oncology?
• Positive Sentiment: AbbVie completed a real-world study of upadacitinib in China and finished a bioavailability study for ABBV-932, both of which support ongoing pipeline development. AbbVie Completes Real World Upadacitinib Study in China AbbVie Advances ABBV-932 With Completed Bioavailability Study
• Neutral Sentiment: AbbVie was also featured in value-stock and “cheap stocks” roundups, which may reflect its appeal to investors but are not direct company-specific catalysts. 5 Best Cheap Stocks to Buy for Beginners June 2026’s Top Stocks Estimated Below Intrinsic Value
• Negative Sentiment: AbbVie ended an early lung cancer trial for ABBV-647, which removes one potential upside driver from the oncology pipeline, though the broader impact appears limited. AbbVie Ends Early Lung Cancer Trial for ABBV-647

AbbVie Stock Up 1.2%

ABBV opened at $227.68 on Friday. The company has a market cap of $402.27 billion, a price-to-earnings ratio of 112.16, a PEG ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81. The firm’s fifty day simple moving average is $209.85 and its two-hundred day simple moving average is $219.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the firm posted $2.46 earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. On average, research analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.